bezalip - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

bezalip

teva pharma (new zealand) limited - bezafibrate 200mg; bezafibrate 200mg - film coated tablet - 200 mg - active: bezafibrate 200mg excipient: colloidal silicon dioxide macrogols magnesium stearate maize starch microcrystalline cellulose opadry white polyvinyl alcohol purified talc sodium starch glycolate starch titanium dioxide active: bezafibrate 200mg excipient: colloidal silicon dioxide kaolin lactose monohydrate macrogols magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polysorbate 80 purified talc sodium citrate dihydrate sodium starch glycolate titanium dioxide - - primary hyperlipidaemia types iia, iib, iii, iv and v (fredrickson classification) corresponding to groups i, ii and iii of the european atherosclerosis society guidelines – when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. - secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

New Zealand - English - Medsafe (Medicines Safety Authority)

bezalip retard

teva pharma (new zealand) limited - bezafibrate 400mg - modified release tablet - 400 mg - active: bezafibrate 400mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 10000 magnesium stearate polymethyl methacrylate polysorbate 80 povidone purified talc sodium citrate dihydrate sodium laurilsulfate titanium dioxide